Therapy of non-alcoholic fatty liver disease: relationship with soluble adhesion molecules


DOI: https://dx.doi.org/10.18565/therapy.2020.4.110-116

Yagoda A.V., Koroy P.V., Slyadnev S.A., Kravchenko Yu.A.

1) Stavropol State Medical University of the Ministry of Healthcare of Russia; 2) Stavropol regional clinical hospital; 3) Municipal Polyclinic No 9, Stavropol
Purpose: assessment of the effect of various treatment options for non-alcoholic fatty liver disease (NAFLD) on soluble adhesion molecules.
Material and methods. The levels of molecules of immunoglobulins superfamily in blood (ICAM-1, VCAM-1, PECAM-1) were investigated in 42 patients with NAFLD in dynamics of 12 weeks of therapy. Patients were divided into three groups: in 1st group combination of hepatoprotective agents and pentoxifylline was applied, in 2nd group combination of hepatoprotective agents and metformin was used, in 3rd group only hepatoprotective agent (phosphogliv forte) was administrated.
Results. Decrease of concentration of all adhesins in blood and normalization of PECAM-1 levels observed in cases of application of hepatoprotective agents and pentoxifylline. During treatment of hepatoprotective agents and metformin reduction of VCAM-1, PECAM-1 blood levels and normalization of ICAM-1 levels were observed. Monotherapy by phosphogliv forte led to decrease in plasma levels of all adhesins, not reaching normal values.
Conclusion. In cases of biochemical remission of NAFLD (normalization of aminotransferases) decrease in blood concentration of all adhesion molecules was present, thus levels of ICAM-1 and PECAM-1 reached normal values. In patients with preservation of increased activity of ASL or ALT in dynamics of treatment only VCAM-1 levels decreased.
Keywords: non-alcoholic fatty liver disease, adhesion molecules, treatment, pentoxifylline, metformin, phosphogliv forte
Read entire article

Literature


  1. Ивашкин В.Т., Маевская М.В., Павлов Ч.С. с соавт. Клинические рекомендации по диагностике и лечению неалкогольной жировой болезни печени Российского общества по изучению печени и Российской гастроэнтерологической ассоциации. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2016; 2: 24–42. [Ivashkin V.T., Mayevskaya M.V., Pavlov Ch.S. et al. Diagnostics and treatment of non-alcoholic fatty liver disease: clinical guidelines of the Russian Scientific Liver Society and the Russian gastroenterological association. Rossiysky zhurnal gastroenterologii, gepatologii i koloproktologii. 2016; 2: 24–42 (In Russ.)]. doi: http://doi.org/10.22416/1382-4376-2016-26-2-24-42

  2. Chalasani N., Younossi Z., Lavine J.E. et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases. Hepatology. 2018; 67(1): 328–57. doi: 10.1002/hep.29367.

  3. Takaki A., Kawai D., Yamamoto K. Multiple hits, including oxidative stress, as pathogenesis and treatment target in non-alcoholic steatohepatitis (NASH). Int J Mol Sci. 2013; 14(10): 20704–28. doi: 10.3390/ijms141020704.

  4. Корой П.В., Ягода А.В., Сляднев С.А. Состояние адгезивной функции эндотелия при неалкогольной жировой болезни печени. Врач. 2017; 5: 19–22. [Koroi P., Yagoda A., Slyadnev S. Endothelial adhesive function in nonalcoholic fatty liver disease. Vrach. 2017; 5: 19–22 (In Russ.)].

  5. Bilgir F., Bilgir O., Calan M. et al. The levels of soluble inter-cellular adhesion molecule, vascular adhesion molecule and se-selectin levels in patients with non-alcoholic fatty liver disease. J Autacoids Horm. 2015; 4(1): 108. doi: 10.4172/2161-0479.1000108.

  6. Ягода А.В., Корой П.В., Сляднев С.А. Положительная корреляция уровня молекул суперемейства иммуноглобулинов ICAM-1, VCAM-1, PECAM-1 с показателями индекса фиброза при неалкогольной жировой болезни печени. Экспериментальная и клиническая гастроэнтерология. 2017; 138(2): 45–51. [Yagoda A.V., Koroy P.V., Slyadnev S.A. Positive correlation of the level of molecules of superfamily immunoglobulins ICAM-1, VCAM-1 and PECAM-1 with the index of fibrosis in nonalcoholic fatty liver disease. Ekperimental'naya i klinicheskaya gastroenterologiya. 2017; 138(2): 45–51 (In Russ)].

  7. Чумакова Г.А., Кузнецова Т.Ю., Дружилов М.А., Веселовская Н.Г. Висцеральное ожирение как глобальный фактор сердечно-сосудистого риска. Российский кардиологический журнал. 2018; 23(5): 7–14. [Chumakova G.A., Kuznetsova T. Yu., Druzhilov M.A., Veselovskaya N.G. Visceral adiposity as a global factor of cardiovascular risk. Rossiysky kardiologichesky zhurnal. 2018; 23(5): 7–14 (In Russ.)]. doi: http://dx.doi.org/10.15829/1560-4071-2018-5-7-14.

  8. Abd El-Kader S.M., Al-Jiffri O.H. Impact of weight reduction on insulin resistance, adhesive molecules and adipokines dysregulation among obese type 2 diabetic patients. Afri Health Sci. 2018; 18(4): 873–83.doi: 10.4314/ahs.v18i4.5.

  9. Rosety I., Pery M.T., Rosety J. et al. Circuit resistance training improved endothelial dysfunction in obese aged women. Nutr Hosp. 2016; 33(1): 131–34. doi: 10.20960/nh.v33i1.17.

  10. 10. Ryan A.S., Ge S., Blumenthal J.B. et al. Aerobic exercise and weight loss reduce vascular markers of inflammation and improve insulin sensitivity in obese women. J Am Geriatr Soc. 2014; 62(4): 607–14. doi: 10.1111/jgs.12749.

  11. Tang L., Peng H., Xu T. et al. Association of biomarkers of inflammation with dyslipidemia and its components among Mongolians in China. PLoS ONE. 2014; 9(2): e89023. doi: 10.1371/journal.pone.0089023.

  12. Журавлева Л.В., Кривоносова Е.М. Влияние сочетанной терапии альфа-липоевой кислотой и бенфотиамином на течение неалкогольной жировой болезни печени. Практикуючий лікар. 2014; 4: 42–47. [Zhuravleva L.V., Krivonosova E.M. Impact of lipoic acid and benfotiamine combination therapy on course of non-alcoholic fatty liver disease. Praktikuyuschiy likar. 2014; 4: 42–47 (In Russ.)].

  13. Pathil A., Mueller J., Warth A. et al. Ursodeoxy-cholyl lysophosphatidylethanolamide improves steatosis and inflammation in murine models of nonalcoholic fatty liver disease. Hepatology. 2012; 55: 1369–78. doi: 10.1002/hep.25531.

  14. Du J., Ma Y.Y., Yu C.H., Li Y.M. Effects of pentoxifylline on nonalcohol-ic fatty liver disease: a meta-analysis. World J Gastroenterol. 2014; 20(2): 569–77. doi: 10.3748/wjg.v20.i2.569.

  15. Комшилова К.А. Абдоминальное ожирение и неалкогольная жировая болезнь печени: клинико-лабораторные и морфологические сопоставления. Автореф. дис. ... канд. мед. наук. М., 2015. [Komshilova K.A. Abdominal obesity and non-alcoholic fatty liver disease: clinical laboratory and morphological comparisons. Abstract of PhD thesis. M. 2015 (In Russ.)].

  16. Brea A., Puzo J. Non-alcoholic fatty liver disease and cardiovascular risk. Int J Cardiol. 2013; 167(4): 1109–17. doi: 10.1016/j.ijcard.2012.09.085.

  17. Li J.Y., Cao H.Y., Liu P. et al. Glycyrrhizic acid in the treatment of liver diseases: literature review. Biomed Res Int. 2014; 2014: 872139. doi: 10.1155/2014/872139.

  18. Mawatari S., Uto H., Tsubouchi H. Chronic liver disease and arteriosclerosis. Nihon Rinsho. 2011; 69(1): 153–57.

  19. Mohammadpour A.H., Falsoleiman H., Shamsara J. et al. Pentoxifylline decreases serum level of adhesion molecules in atherosclerosis patients. Iran. Biomed. J. 2014; 18(1): 23–27. doi: 10.6091/ibj.1211.2013.

  20. Green L.A., Kim C., Gupta S.K. et al. Pentoxifylline reduces tumor necrosis factor-α and HIV-induced vascular endothelial activation. AIDS Res Hum Retroviruses. 2012; 28(10): 1207–15. doi: 10.1089/aid.2011.0385.

  21. Kruszelnicka O., Chyrchel B., Golay A., Surdacki A. Differential associations of circulating asymmetric dimethylarginine and cell adhesion molecules with metformin use in patients with type 2 diabetes mellitus and stable coronary artery disease. Amino. Acids. 2015; 47(9): 1951–59. doi: 10.1007/s00726-015-1976-3.

  22. Victor V.M., Rovira-Llopis S., Banuls C. et al. Metformin modulates human leukocyte/endothelial cell interactions and proinflammatory cytokines in polycystic ovary syndrome patients. Atherosclerosis. 2015; 242(1): 167–73. doi: 10.1016/j.atherosclerosis.2015.07.017.

  23. Han J., Li Y., Liu X. et al. Metformin suppresses retinal angiogenesis and inflammation in vitro and in vivo. PLoS ONE. 2018; 13(3): e0193031. doi: 10.1371/journal.pone.0193031.

  24. Hocaoglu-Emre F.S., Saribal D., Yenmis G., Guvenen G. Vascular cell adhesion molecule 1, intercellular adhesion molecule 1, and cluster of differ-entiation 146 levels in patients with type 2 diabetes with complications. En-docrinol. Metab. (Seoul). 2017; 2(1): 99–105. doi: 10.3803/EnM.2017.32.1.99.

  25. Wang Z.H., Hsieh C.H., Liu W.H., Yin M.C. Glycyrrhizic acid attenuated glycativestress in kidney of diabetic mice through enhancing glyoxalase pathway. Mol Nutr Food Res. 2014; 58(7): 1426–35. doi: 10.1002/mnfr.201300910.

  26. Zhou J. X., Wink M. Evidence for anti-inflammatory activity of isoliquiriti-genin, 18β glycyrrhetinic acid, ursolic acid, and the traditional Chinese medicine plants Glycyrrhiza glabra and Eriobotrya japonica, at the molecular level. Medicines (Basel). 2019; 6(2): E55. doi: 10.3390/medicines6020055.

  27. Xiong H., Xu Y., Tan G. et al. Glycyrrhizin ameliorates imiquimod-induced psoriasis-like skin lesions in BALB/c mice and inhibits TNF-α-induced ICAM-1 expression via NF-κB/MAPK in HaCaT cells. Cell. Physiol. Biochem. 2015; 35(4): 1335–46. doi: 10.1159/000373955.

  28. Wang Y.M., Du G.Q. Glycyrrhizic acid prevents enteritis through reduction of NF κB p65 and p38MAPK expression in rat. Mol. Med. Rep. 2016; 13(4): 3639–46. doi: 10.3892/mmr.2016.4981.

  29. Wang W., Zhao F., Fang Y. et al. Glycyrrhizin protects against porcine endotoxemia through modulation of systemic in-flammatory response. Crit. Care. 2013; 17(2): R44. doi: 10.1186/cc12558.


About the Autors

Alexander V. Yagoda, MD, PhD, professor, head of Department of hospital therapy Stavropol State Medical University of the Ministry of Healthcare of Russia, Honored worker of science of Russian Federation. Address: 355017, Stavropol, 310 Mira str. Tel.: +7 (865) 229-53-09. E-mail: alexander.yagoda@gmail.com
Pavel V. Koroy, MD, PhD, professor of Department of hospital therapy Stavropol State Medical University of the Ministry of Healthcare of Russia. Address: 355017, Stavropol, 310 Mira str. Tel.: +7 (865)271-35-37. E-mail: paule75@yandex.ru
Sergey A. Slyadnev, doctor of Gastroenterology Department of Stavropol regional clinical hospital. Address: 355000, Stavropol, 208 Lermontova str, Tel.: +7 (865) 271-32-12. E-mail: bboyscud2011@mail.ru
Yuliya A. Kravchenko, therapist of Municipal Polyclinic No 9. Address: 355000, Stavropol, 42 Yunosti prospect.
Tel.: +7 (865) 299-89-89. E-mail: rudenchy@mail.ru

Back to Content

Бионика Медиа